[go: up one dir, main page]

CL2011002781A1 - Compuestos (e)-2-(4-(2-(5-(1-(3,5-dicloropiridin-4-il)etoxi)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol y (r)-(e)-2-(4-(2-(5-(1-(3,5-dicloropiridin-4-il)etoxi)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol; composicion farmaceutica que los comprende; y uso en el tratamiento del cancer. - Google Patents

Compuestos (e)-2-(4-(2-(5-(1-(3,5-dicloropiridin-4-il)etoxi)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol y (r)-(e)-2-(4-(2-(5-(1-(3,5-dicloropiridin-4-il)etoxi)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol; composicion farmaceutica que los comprende; y uso en el tratamiento del cancer.

Info

Publication number
CL2011002781A1
CL2011002781A1 CL2011002781A CL2011002781A CL2011002781A1 CL 2011002781 A1 CL2011002781 A1 CL 2011002781A1 CL 2011002781 A CL2011002781 A CL 2011002781A CL 2011002781 A CL2011002781 A CL 2011002781A CL 2011002781 A1 CL2011002781 A1 CL 2011002781A1
Authority
CL
Chile
Prior art keywords
dichloropyridin
indazol
vinyl
ethanol
ethoxy
Prior art date
Application number
CL2011002781A
Other languages
English (en)
Inventor
Hong-Yu Li
Genshi Zhao
Daohong Chen
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CL2011002781A1 publication Critical patent/CL2011002781A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

COMPUESTO E)-2 -( 4-( 2-(5-(1-(3,5-DICLOROPIRIDIN-4-IL)ETOXI)-1H-INDAZOL-3-IL)VINIL)-1H-PIRAZOL-1-IL)ETANOL Y (R)-(E)-2-<br /> (4-( 2-(5-( 1-(3,5-DICLOROPIRIDIN-4-IL)ETOXI)-1H-INDAZOL-3-IL )VINIL)-1H-PIRAZOL-1-IL)ETANOL; COMPOSICIÓN FARMACÉUTICA<br /> QUE LOS COMPRENDE; Y USO EN EL TRATAMIENTO DEL CÁNCER.<br />  
CL2011002781A 2009-05-07 2011-11-07 Compuestos (e)-2-(4-(2-(5-(1-(3,5-dicloropiridin-4-il)etoxi)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol y (r)-(e)-2-(4-(2-(5-(1-(3,5-dicloropiridin-4-il)etoxi)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol; composicion farmaceutica que los comprende; y uso en el tratamiento del cancer. CL2011002781A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17629009P 2009-05-07 2009-05-07
US30141610P 2010-02-04 2010-02-04

Publications (1)

Publication Number Publication Date
CL2011002781A1 true CL2011002781A1 (es) 2012-05-25

Family

ID=42238704

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011002781A CL2011002781A1 (es) 2009-05-07 2011-11-07 Compuestos (e)-2-(4-(2-(5-(1-(3,5-dicloropiridin-4-il)etoxi)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol y (r)-(e)-2-(4-(2-(5-(1-(3,5-dicloropiridin-4-il)etoxi)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol; composicion farmaceutica que los comprende; y uso en el tratamiento del cancer.

Country Status (34)

Country Link
US (1) US8268869B2 (es)
EP (1) EP2427449B1 (es)
JP (1) JP5555314B2 (es)
KR (1) KR101373910B1 (es)
CN (1) CN102421769B (es)
AR (1) AR078411A1 (es)
AU (1) AU2010246114B2 (es)
BR (1) BRPI1013748A2 (es)
CA (1) CA2760535C (es)
CL (1) CL2011002781A1 (es)
CO (1) CO6450624A2 (es)
CR (1) CR20110580A (es)
DK (1) DK2427449T3 (es)
EA (1) EA018149B1 (es)
EC (1) ECSP11011441A (es)
ES (1) ES2408117T3 (es)
HN (1) HN2011002809A (es)
HR (1) HRP20130323T1 (es)
IL (1) IL216004A (es)
JO (1) JO2860B1 (es)
MA (1) MA33244B1 (es)
ME (1) ME01462B (es)
MX (1) MX2011011342A (es)
MY (1) MY160390A (es)
NZ (1) NZ595553A (es)
PE (2) PE20120812A1 (es)
PL (1) PL2427449T3 (es)
PT (1) PT2427449E (es)
RS (1) RS52795B (es)
SG (1) SG175909A1 (es)
SI (1) SI2427449T1 (es)
TW (1) TWI382982B (es)
UA (1) UA104756C2 (es)
WO (1) WO2010129509A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3062B1 (ar) * 2010-10-05 2017-03-15 Lilly Co Eli R)-(e)-2-(4-(2-(5-(1-(3، 5-داي كلورو بيريدين-4-يل)إيثوكسي)-1h-إندازول-3-يل)?ينيل)-1h-بيرازول-1-يل)إيثانول بلوري
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
MX365214B (es) 2012-03-08 2019-05-27 Astellas Pharma Inc Nuevo producto de fusion de fgfr3.
ES2984771T3 (es) 2012-06-13 2024-10-31 Incyte Holdings Corp Compuestos tricíclicos sustituidos como inhibidores de FGFR
US20150203589A1 (en) 2012-07-24 2015-07-23 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
EP2968551B1 (en) 2013-03-15 2021-05-05 The Trustees of Columbia University in the City of New York Fusion proteins and methods thereof
EA035095B1 (ru) 2013-04-19 2020-04-27 Инсайт Холдингс Корпорейшн Бициклические гетероциклы в качестве ингибиторов fgfr
CN103819396B (zh) * 2014-02-26 2016-06-15 四川大学 一种手性的1-（3,5-二氯吡啶-4-基）-乙醇的合成方法
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
WO2016105517A1 (en) 2014-12-23 2016-06-30 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
EA038045B1 (ru) 2015-02-20 2021-06-28 Инсайт Корпорейшн Бициклические гетероциклы в качестве ингибиторов fgfr
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
CN105906621A (zh) * 2015-04-06 2016-08-31 四川百利药业有限责任公司 用作fgfr抑制剂的乙醇类化合物
WO2016187767A1 (en) * 2015-05-25 2016-12-01 Hutchison Medipharma Limited Pharmaceutical compositions and use thereof
CN107922349B (zh) * 2015-08-07 2021-05-07 哈尔滨珍宝制药有限公司 作为fgfr和vegfr抑制剂的乙烯基化合物
EP3339305B1 (en) 2015-08-20 2022-05-04 Zhejiang Hisun Pharmaceutical Co., Ltd Indole derivative, preparation method thereof, and use thereof in pharmaceutical drug
CN107459519A (zh) 2016-06-06 2017-12-12 上海艾力斯医药科技有限公司 稠合嘧啶哌啶环衍生物及其制备方法和应用
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
RS66310B1 (sr) 2018-05-04 2025-01-31 Incyte Corp Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu
US11174257B2 (en) 2018-05-04 2021-11-16 Incyte Corporation Salts of an FGFR inhibitor
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
PH12022550892A1 (en) 2019-10-14 2023-05-03 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021088859A1 (zh) * 2019-11-06 2021-05-14 暨南大学 吲唑类化合物及其药用组合物和应用
AU2020395185A1 (en) 2019-12-04 2022-06-02 Incyte Corporation Derivatives of an FGFR inhibitor
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US12441707B2 (en) 2019-12-30 2025-10-14 Tyra Biosciences, Inc. Indazole compounds
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2022033472A1 (zh) * 2020-08-11 2022-02-17 河南迈英诺医药科技有限公司 Fgfr抑制剂化合物及其用途
JP2024513575A (ja) 2021-04-12 2024-03-26 インサイト・コーポレイション Ｆｇｆｒ阻害剤及びネクチン－４標的化剤を含む併用療法
WO2022261160A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
TW202313610A (zh) 2021-06-09 2023-04-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之三環雜環
CN116554148B (zh) * 2022-12-13 2025-01-28 药康众拓(北京)医药科技有限公司 一种乙烯基吲唑类氘代fgfr抑制剂药物及用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
KR100732206B1 (ko) 2000-09-11 2007-06-27 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 티로신 키나제 억제제로서의 퀴놀리논 유도체
EP1447405A4 (en) * 2001-10-17 2005-01-12 Kirin Brewery CHINOLIN OR CHINAZOLINE DERIVATIVES THAT PREVENT THE AUTOPHOSPHORYLATION OF RECEPTORS FOR THE FIBROBLAST GROWTH FACTOR
TW200406385A (en) * 2002-05-31 2004-05-01 Eisai Co Ltd Pyrazole compound and pharmaceutical composition containing the same
DE10342503A1 (de) * 2003-09-12 2005-04-14 Merck Patent Gmbh Benzyl-Benzimidazolylderivate
ATE404560T1 (de) 2004-05-26 2008-08-15 Pfizer Indazol- und indolonderivative und deren verwendung als pharmazeutika
WO2007058626A1 (en) 2005-11-16 2007-05-24 S*Bio Pte Ltd Indazole compounds
EP1963320A1 (en) * 2005-12-07 2008-09-03 OSI Pharmaceuticals, Inc. Pyrrolopyridine kinase inhibiting compounds
CA2673095C (en) 2006-12-20 2016-03-15 Nerviano Medical Sciences S.R.L. Indazole derivatives as kinase inhibitors for the treatment of cancer
US7737149B2 (en) * 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
KR20100025553A (ko) 2007-06-05 2010-03-09 쉐링 코포레이션 암 치료용 ｅｒｋ 억제제로서의 폴리사이클릭 인다졸 유도체 및 이의 용도
DE102007028521A1 (de) 2007-06-21 2008-12-24 Merck Patent Gmbh Indazolamidderivate
JP2011511005A (ja) * 2008-02-04 2011-04-07 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド ２−アミノピリジン系キナーゼ阻害薬

Also Published As

Publication number Publication date
TW201105652A (en) 2011-02-16
EP2427449A1 (en) 2012-03-14
HK1163665A1 (en) 2012-09-14
TWI382982B (zh) 2013-01-21
KR101373910B1 (ko) 2014-03-12
JP5555314B2 (ja) 2014-07-23
IL216004A (en) 2014-01-30
SG175909A1 (en) 2011-12-29
CA2760535C (en) 2014-01-14
MA33244B1 (fr) 2012-05-02
UA104756C2 (uk) 2014-03-11
ME01462B (me) 2014-04-20
CA2760535A1 (en) 2010-11-11
US20100286209A1 (en) 2010-11-11
JO2860B1 (en) 2015-03-15
PT2427449E (pt) 2013-05-06
EP2427449B1 (en) 2013-04-03
US8268869B2 (en) 2012-09-18
IL216004A0 (en) 2012-01-31
RS52795B (sr) 2013-10-31
MY160390A (en) 2017-03-15
HRP20130323T1 (en) 2013-05-31
HN2011002809A (es) 2013-07-22
NZ595553A (en) 2013-05-31
ECSP11011441A (es) 2011-12-30
AR078411A1 (es) 2011-11-09
PE20160124A1 (es) 2016-02-24
CN102421769B (zh) 2014-04-02
MX2011011342A (es) 2011-11-18
EA018149B1 (ru) 2013-05-30
CN102421769A (zh) 2012-04-18
PE20120812A1 (es) 2012-07-08
AU2010246114A1 (en) 2011-11-03
KR20120004511A (ko) 2012-01-12
CO6450624A2 (es) 2012-05-31
SI2427449T1 (sl) 2013-05-31
ES2408117T3 (es) 2013-06-18
CR20110580A (es) 2012-01-06
JP2012526126A (ja) 2012-10-25
EA201171367A1 (ru) 2012-04-30
PL2427449T3 (pl) 2013-08-30
BRPI1013748A2 (pt) 2016-04-05
WO2010129509A1 (en) 2010-11-11
AU2010246114B2 (en) 2012-12-06
DK2427449T3 (da) 2013-04-22

Similar Documents

Publication Publication Date Title
CL2011002781A1 (es) Compuestos (e)-2-(4-(2-(5-(1-(3,5-dicloropiridin-4-il)etoxi)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol y (r)-(e)-2-(4-(2-(5-(1-(3,5-dicloropiridin-4-il)etoxi)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol; composicion farmaceutica que los comprende; y uso en el tratamiento del cancer.
EA201390275A1 (ru) Кристаллический (r)-(e)-2-(4-(2-(5-(1-(3,5-дихлорпиридин-4-ил)этокси)-1h-индазол-3-ил)винил)-1h-пиразол-1-ил)этанол
UY33397A (es) Forma sólida de un naftaleno carboxamida
CL2008002097A1 (es) Compuestos derivados de heterociclos condensados sustituidos, inhibidores de cinasa de fosfatidil-inositol-3; composicion farmaceutica; y uso en el tratamiento del cancer.
CL2008002521A1 (es) Compuestos derivados de pirazol sustituidos, antagonista del receptor de androgeno; composicion farmaceutica que comprende a dichos compuestos; y uso del compusto para el tratamiento de cancer.
CL2008002369A1 (es) Compuestos derivados de piridin-3-il-oxipiridin-2-il-amino, inhibidores de alk5; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del cancer.
CL2008000795A1 (es) Uso de 1-[2-(2,4-dimetilfenilsulfanil)fenil)piperazina para el tratamiento del dolor o de los sintomas residuales de la depresion; y dicho compuesto.
AR067813A1 (es) Fenilendiaminas sustituidas como inhibidores de l ainteraccion entre mdm2 y p53
CL2007002167A1 (es) Compuestos derivados de indol, antagonistas iap; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de cancer.
UA99621C2 (xx) Похідні піридазинону$производные пиридазинона
CL2009000882A1 (es) Un compuesto n-(4-cloro-3-(piridin-2-il)fenil)-4-(2-hidroxi-2-metilpropilsulfonil)-2-metilbenzamida, inhibidor de la via de señalización hedgehog; composición farmacéutica que comprende a dicho compuesto; y su uso para tratar el cancer.
PE20130239A1 (es) Compuestos heteroaril-aril-ureas como inhibidores de la quinasa
ECSP11010825A (es) Dabigatrán para la cateterización cardiaca intervencionista percutanea.
CL2009000906A1 (es) Compuestos derivados de 4-imidazolil y 4-triazolil de 2-(6-(4-cicloalquilpiperazin-1-il)pirimidin-4-il)-1h-pirazol-3(2h)ona inhibidores de hif-prolil-4-hidroxilasas; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto en el tratamiento de enfermedades cardiovasculares, renales y hematologicas.
MX2010001485A (es) Derivado de fenoxi-pirrolidina y su uso, y composiciones.
NO341679B1 (no) Substituerte pyridylamidforbindelser, fremstilling av slike og farmasøytiske sammensetninger inneholdende slike, samt anvendelse som modulatorer av histamin H3-reseptoren
CL2007000595A1 (es) Compuestos derivados de piperidina; composicion farmaceutica y uso para el tratamiento y/o profilaxis de enfermedades seleccionadas entre hipertension, insuficiencia cardiaca congestiva e insuficiencia renal entre otras.
CL2007003251A1 (es) Compuestos derivados de 1h-pirazoles sustituidos, inhibidores de reacciones catalizadas por una quinasa; su procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios; uso de los compuestos principales, utiles en el tratamiento del cancer.
DOP2018000134A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer
ECSP10010379A (es) Derivados de oxindol sustituido y su uso para el tratamiento de enfermedades dependientes de la vasopresina
EP3845528C0 (en) PYRAZOLE COMPOUNDS, CORRESPONDING PHARMACEUTICAL COMPOSITIONS AND USE THEREOF AS IRAK4 INHIBITORS
NO20065231L (no) Nye imidazoler
UY31337A1 (es) Nuevos compuestos farmaceuticos
CY1117146T1 (el) Κρυσταλλικη (r)-(ε)-2-(4-(2-(5-(1-(3,5-διχλωροπυριδινο-4-υλ)αιθοξυ)-1 η-ινδαζολο-3-υλ)βινυλο)-1 η-πυραζολο-1-υλ)αιθανολη και η χρηση της ως αναστολεα του fgfr
TN2013000142A1 (en) Crystalline (r) - (e) -2- (4- (2- (5- (1- (3, 5 -dichloropyridin-4 -yl) ethoxy) - 1h - indazol - 3 - yl) vinyl) -1 h- pyrazol- 1 -yl) ethanol and its use as fgfr inhibitor